We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-2.22%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$415M
AUM Growth
-$201M
Cap. Flow
-$160M
Cap. Flow %
-38.55%
Top 10 Hldgs %
36.85%
Holding
112
New
24
Increased
13
Reduced
25
Closed
42
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QTNT
101
DELISTED
Quotient Limited Ordinary Shares
QTNT
-1,500
Closed -$469K
GWPH
102
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
-100,000
Closed -$13.3M
GHDX
103
DELISTED
Genomic Health, Inc.
GHDX
-75,000
Closed -$2.17M
ALDR
104
DELISTED
Alder Biopharmaceuticals
ALDR
-16,000
Closed -$524K
HZNP
105
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
-225,000
Closed -$4.08M
ELGX
106
DELISTED
Endologix Inc
ELGX
-30,000
Closed -$3.84M
KTWO
107
DELISTED
K2M Group Holdings, Inc
KTWO
-175,000
Closed -$3.11M
KITE
108
CALL
DELISTED
Kite Pharma, Inc.
KITE
-65,000
Closed -$3.63M
PTHN
109
DELISTED
Patheon N.V.
PTHN
-275,700
Closed -$4.3M
CYNO
110
DELISTED
Cynosure, Inc. Class A
CYNO
-150,000
Closed -$7.64M
ARIA
111
PUT
DELISTED
Ariad Pharmaceuticals Inc
ARIA
-100,000
Closed -$1.37M
CELG
112
CALL
DELISTED
Celgene Corp
CELG
-75,000
Closed -$7.84M

Similar funds

Ghost Tree Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Ghost Tree Capital held 112 positions worth $415M, down 33% from $617M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Ghost Tree Capital withdrew a net $160M in Q4 2016, closing 42 positions and reducing 25 holdings. Its most notable exit was Edwards Lifesciences, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 51% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Shire pic worth $17M.

  • Ghost Tree Capital's largest Q4 2016 buy was Shire pic: 100,000 shares worth $17M.
  • Ghost Tree Capital added most to AveXis, Inc. Common Stock in Q4 2016, an estimated $7.93M increase.
  • Ghost Tree Capital's biggest Q4 2016 reduction was Clovis Oncology, Inc., cutting an estimated $9.85M.
  • Ghost Tree Capital fully exited Edwards Lifesciences in Q4 2016, selling an estimated $10.2M.
  • Ghost Tree Capital's ten largest holdings make up 37% of its $415M portfolio in Q4 2016.
  • Ghost Tree Capital opened 24 new positions and closed 42 in Q4 2016.
  • Ghost Tree Capital's portfolio value fell 33% quarter-over-quarter to $415M.

Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.